A recent survey conducted by ORC International and commissioned by Change Healthcare found payers are seeing, on average, savings of about 5.6 percent in medical costs from value-based contracts, but some concerns remain, according to an eyeforpharma report.
While the survey found that payers also reported improved health care quality, provider relationships and patient engagement, more than half of those surveyed were dissatisfied with analytics, automation and reporting.
Dan Leonard, National Pharmaceutical Council president and CEO, remains optimistic about the future of value-based deals.
“We hear from payers and manufacturers that the impact is either neutral to positive in terms of improving patient access to treatments,” Leonard said. “There are very few negative reports out there.”